Targeting the Epidermal Growth Factor Receptor in EGFR-Mutated Lung Cancer: Current and Emerging Therapies

Targeting the Epidermal Growth Factor Receptor in EGFR-Mutated Lung Cancer: Current and Emerging Therapies

Epidermal growth factor receptor-targeting tyrosine kinase inhibitors (EGFR TKIs) are the standard of care for patients with EGFR-mutated metastatic lung cancer. While EGFR TKIs have initially high response rates, inherent and acquired resistance constitute a major challenge to the longitudinal trea...

Full description

Bibliographic Details
Main Authors: Karam Khaddour, Sushma Jonna, Alexander Deneka, Jyoti D. Patel, Mohamed E. Abazeed, Erica Golemis, Hossein Borghaei, Yanis Boumber
Format: Article
Language:English
Published: MDPI AG 2021-06-01
Series:Cancers
Subjects:
lung cancer
adenocarcinoma
overall survival
EGFR
tyrosine kinase inhibitors
progression-free survival
Online Access:https://www.mdpi.com/2072-6694/13/13/3164

Internet

https://www.mdpi.com/2072-6694/13/13/3164

Similar Items